GlassScriptPhysician profile
James Marshall Chapman
NPI 1275584914
$4,771.88
in general payments reported to CMS, 2019-2025
48 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,615 · 2020: $311 · 2021: $636 · 2022: $256 · 2023: $411 · 2024: $651 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $609.24 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $518.57 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $483.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $306.17 | 2019-2025 | Vraylar, Qulipta |
| Pfizer INC. | $288.55 | 2019-2025 | |
| Amgen INC. | $279.18 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $252.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $224.24 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.06 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $146.34 | 2019-2020 | |
| Astellas Pharma US INC | $113.84 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $86.41 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $84.09 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $82.83 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.64 | 2019-2025 | Jardiance |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.